Immatics N.V.
$9.50+0.7%1Y+76.6%
Mentions · last 7 days
43
Price updated 2h ago·X counts updated 4h ago
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Biotechnology sits in its cycle right now — and what that implies for $IMTX.
Biotechnology
GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.
What this means for $IMTX
Partial — fee-based midstream revenue has limited direct commodity price exposure but volume ties to upstream production activity.
Top industry ETF
$IBBiShares Biotechnology ETF
+12.1%YTD
+50.1%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
-5.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
-52.8%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
-5.4%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
-19.2%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
26.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
-47.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
77.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q2 2026Aug 18, 2026$-0.53$-0.48-10.5%
Q1 2026May 12, 2026$-0.50$-0.42-19.0%
Q4 2025Mar 5, 2026$-0.34$-0.48+29.2%
Q3 2025Nov 17, 2025$-0.49$-0.44-11.5%
Next earningsTue, Nov 17·consensus EPS $-0.58
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$9.1M+93.0%100%-735%$-0.46$-62.1M
Q1 FY26$7.6M-59.0%100%-868%$-0.43$-43.5M
Q4 FY25$19.8M-64.9%100%-197%$-0.28$-58.6M
Q3 FY25$5.2M-89.7%100%-1053%$-0.42$-45.8M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$44.5M$25.7M – $65.2M-$2.11-$2.45 – -$1.805
FY27$37.4M$21.6M – $54.8M-$2.20-$2.98 – -$1.715
FY28$117.8M$16.1M – $239.4M-$1.92-$2.53 – -$1.487
FY29$240.2M$138.5M – $351.8M-$1.06-$1.70 – -$0.483
FY30$459.7M$265.1M – $673.4M-$0.15-$0.25 – -$0.075
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.60%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+0.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-5.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatMid float · 112.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.325-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal MelanomaImmatics Announces $150 Million Underwritten OfferingImmatics Announces Second Quarter 2026 Financial Results and Business UpdateAnalysts Set Immatics N.V. (NASDAQ:IMTX) Target Price at $20.80Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
More in Biotechnology
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · top 1 · last 7 days